PHYSIOMICS PLC |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1.25 GBX | 0.00% |
|
0.00% | -21.88% |
| 03/05 | Physiomics warns large contracts taken longer than expected | AN |
| 03/05 | AIM WINNERS & LOSERS: Fletcher King optimistic; Angle in Astra deal | AN |
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Last Hours!
Take advantage of the offer
* See conditions on site
| Sales 2024 * | 625K 794K 66.11M | Sales 2025 * | - | Capitalization | 1.69M 2.15M 179M |
|---|---|---|---|---|---|
| Net income 2024 * | - 0 0 | Net income 2025 * | - | EV / Sales 2024 * | 2.42 x |
| Net cash position 2024 * | 180K 229K 19.04M | Net cash position 2025 * | - 0 0 | EV / Sales 2025 * | - |
| P/E ratio 2024 * |
-2.78
x | P/E ratio 2025 * |
-
| Employees | 10 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 93.74% |
More Fundamentals
* Assessed data
More news
Latest transcript on Physiomics Plc
| Current month | -19.35% | ||
| 1 month | +8.70% | ||
| 3 months | -10.71% | ||
| 6 months | -26.47% | ||
| Current year | -21.88% |
1 week
1.12
1.29
1 month
1.031.67
Current year
1.032.10
1 year
0.903.19
3 years
0.907.94
5 years
0.9017.25
10 years
0.9032.00
| Managers | Title | Age | Since |
|---|---|---|---|
Peter Sargent
CEO | Chief Executive Officer | - | 05/23/05 |
Jim Millen
CHM | Chairman | 55 | 18/16/18 |
| Director of Finance/CFO | 50 | - |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Timothy Corn
BRD | Director/Board Member | 73 | 01/22/01 |
| Chief Tech/Sci/R&D Officer | 54 | 01/04/01 | |
Shalabh Kumar
BRD | Director/Board Member | - | 01/22/01 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 17/24/17 | 1.25 | 0.00% | 181 775 |
| 16/24/16 | 1.25 | 0.00% | 0 |
| 15/24/15 | 1.25 | 0.00% | 11,000 |
| 14/24/14 | 1.25 | 0.00% | 152,646 |
| 13/24/13 | 1.25 | 0.00% | 40,000 |
Delayed Quote London S.E., May 17, 2024 at 09:05 pm IST
More quotes
Physiomics PLC is a United Kingdom-based company, which provides consulting services to pharmaceutical companies in the areas of outsourced quantitative pharmacology and computational biology. The Company offer its services by utilizing its proprietary Virtual Tumour predictive software, industry standard tools (such as NONMEM and MATLAB), as well as developing bespoke models using the R programming language. Virtual Tumour is a predictive quantitative systems' pharmacology (QSP) model used worldwide by global pharmaceuticals to small biotech companies to support oncology Research and development (R&D). It is a semi-mechanistic model that incorporates an abstracted representation of the cell cycle, Deoxyribonucleic acid (DNA) damage/ repair and elements of the immune response. The Company is also developing its technology for use in the field of personalized medicine. The Company is focused on helping pharma and biotech clients.
Calendar
26/09/2024
- Q4 2024 Earnings Release (Projected)
Trading Rating
Investor Rating
ESG Refinitiv
EPS Revisions
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -21.88% | 2.15M | |
| +20.24% | 77.08B | |
| -11.04% | 39.41B | |
| +13.91% | 37.93B | |
| +0.48% | 30.9B | |
| -6.37% | 16.98B | |
| +13.21% | 15.31B | |
| +9.23% | 10.56B | |
| -9.02% | 4.73B | |
| -34.99% | 4.13B |
- Stock Market
- Equities
- PYC Stock
